ClinicalTrials.gg
RecruitingNCT06620562Updated Aug 8, 2025

Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet

A Phase 4 interventional study of Naltrexone/Bupropion and Placebo in Obesity; Drug and Obesity, Morbid, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-08.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Laval University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.

Planned enrollment
6th of 22
108 · median 57
Started
2025
the only one that year
Phase 4
3 of 32
1 open now
Registered
30th of 32
by date
Lead sponsor
8 of 32
Laval University

Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 4, and was the 30th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity, Morbid with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors.

Researchers will compare SG-NB group with SG-placebo group to see if they experience significantly higher excess weight loss (EWL) at 12 and 24 months and if there is a significantly higher percentage of patients with an EWL above 50% in the SG-NB group versus in the SG-placebo group.

Participants will be randomized 1:1 to SG in combination with NB versus SG with placebo. Patients will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release or placebo. Duration of therapy will be 24 months.Both groups will benefit from behavioral and nutritional support.

03

Conditions studied

  • Obesity; Drug
  • Obesity, Morbid

Browse trials for

04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 108 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MBI above 30 kg/m2 with obesity-related comorbidity or above 35 kg/m2 without associated comorbidities.

Exclusion criteria

Exclusion Criteria:

  • Revisional or reoperative surgery
  • Pregnancy or planned pregnancy in the next 24 months
  • Simultaneous use of other weight loss medication
  • Uncontrolled hypertension
  • Chronic opioid use or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal.
  • Use of other bupropion-containing products
  • Concomitant administration of monoamine oxidase inhibitors.
  • End-stage liver or kidney disease
  • Concomitant use of CYP2B6 inhibitors (ticlopidine or clopidogrel)
  • Concomitant administration of the antipsychotic thioridazine
  • Seizure disorder or a history of seizures
  • Cardiac pacemaker
  • Current or prior diagnosis of bulimia or anorexia nervosa
06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Naltrexone/Bupropion

    Patients will be started one month after sleeve gastrectomie on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects.

    Drug: Naltrexone/Bupropion

  • Placebo comparator
    Placebo

    Patients will be started one month after sleeve gastrectomie on a progressive numbers of matched placebo tablets up to 2 tabs twice a day

    Drug: Placebo

Interventions

  • DrugNaltrexone/Bupropion

    Drug pages: NaltrexoneStudies of NaltrexoneNaltrexone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BupropionStudies of BupropionBupropion pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patient randomized in the Neltrexone/Bupropion group will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects to improve long-term use. Duration of therapy will be 24 months.

  • DrugPlacebo

    Patient randomized in the placebo group will be started one month after surgery on a progressive numbers of matched placebo tablets up to 2 tabs twice a day. Duration of therapy will be 24 months.

07

What researchers measure

Primary outcomes

  1. Weight loss

    % Excess weight loss

    Time frame: baseline to 24 months

  2. Percentage of participant with an Excess Weight Loss above 50%

    Time frame: Baseline to 24 months

Secondary outcomes

  1. Resolution of associated comorbidities

    Type 2 diabetes, hypertension and dislipidemia

    Time frame: Baseline to 24 months

  2. Improvement of Eating behaviors (Food Craving State Questionnaire)

    Evaluates severity of cravings using a validated questionnaire. Minimum : 15; Maximum : 75; Higher scores mean a worse outcome.

    Time frame: Baseline to 24 months

  3. Improvement of Eating behaviors (Food Craving Trait Questionnaire)

    Evaluates severity of cravings using a validated questionnaire. Minimum : 39; Maximum : 234; Higher scores mean a worse outcome.

    Time frame: Baseline to 24 months

  4. Decrease in food explicit and implicit wanting and liking food reward.

    Decrease in food explicit and implicit wanting and liking food reward assessed by Leeds Food Preference Questionnaire using a computerized behavioural task

    Time frame: Baseline to 24 month

  5. Improvement in well-being, mood and Quality of Life (SF-36)

    36-item short form survey evaluating quality of life on a scale from 0 to 100, higher scores indicate better quality of life

    Time frame: Baseline to 24 months

  6. Improvement in well-being, mood and Quality of Life (QLaval)

    Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7, higher scores indicate better quality of life

    Time frame: Baseline to 24 months

  7. Improvement in well-being, mood and Quality of Life (HAD questionnaire)

    HAD questionnaire includes 14 rated items from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), obtaining two scores (maximum score of each score = 21). Higher scores indicate a worse outcome

    Time frame: Baseline to 24 months

  8. Gastro-intestinal side-effects

    Gastro-intestinal side-effects assessed by GIQLI questionnaire on a scale from 0 to 144. Higher scores indicate better quality of life

    Time frame: Baseline to 24-month

  9. Improvement of Eating behaviors (Binge Eating Scale)

    To assess the presence of certain binge eating behaviors that may be indicative of an eating disorder. The higher the score, the more binge eating behaviors is observed. The minimum score is 0 while the maximum score is 46. The final result allows to say if the person has an absent (less than 17), moderate (between 18 and 26) or severe (more than 27) binging level.

    Time frame: Baseline to 24 months

  10. Improvement of Eating behaviors (YFAS 2.0)

    The YFAS 2.0 was designed to assess food addiction. It assesses the symptoms of food addiction and the resulting distress and impaired functioning. The higher the level of symptoms, the more severe the food addiction. Impaired functioning and distress are scored from 0 to 2. Symptoms are scored from 0 to 11. If the functioning and distress score is 1 and above, the food addiction may be mild (2-3 symptoms), moderate (4-5 symptoms), or severe (6+ symptoms).

    Time frame: Baseline to 24 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Oct 1, 2024
StartActual
Jun 4, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Aug 2028
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06620562
Lead sponsor
Laval University
Responsible party
Laurent Biertho (Principal Investigator, Laval University) — Principal investigator
First posted
Oct 1, 2024
Start date
Jun 4, 2025
Primary completion
Jun 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 8, 2025

Study contacts

Mélanie Nadeau
Contact
melanie.nadeau@criucpq.ulaval.ca
4186568711

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Bupropion

Start the discussion